APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon

PLoS Genetics

Volumn 8, Issue 3, 2012, Pages

  Armitage, Andrew E ^a   Deforche, Koen ^b   Chang, Chih hao ^a   Wee, Edmund ^a   Kramer, Beatrice ^c   Welch, John J ^d   Gerstoft, Jan ^e   Fugger, Lars ^a,f   McMichael, Andrew ^a   Rambaut, Andrew ^g   Iversen, Astrid K N ^a,h  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; GUANINE; VIF PROTEIN; APOBEC3G PROTEIN, HUMAN; CYTIDINE DEAMINASE; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; PROTEIN PROTEIN INTERACTION; VIRUS MUTATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; PROVIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

CYTIDINE DEAMINASE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MUTATION; PROVIRUSES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84859248538     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1002550     Document Type: Article

References (78)

1. Rambaut A, Posada D, Crandall KA, Holmes EC, (2004) The causes and consequences of HIV evolution. Nat Rev Genet 5: 52-61.
2. Hache G, Mansky LM, Harris RS, (2006) Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev 8: 148-57.
3. Malim MH, (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364: 675-87.
4. Simon V, Zennou V, Murray D, Huang Y, Ho DD, et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog 1: e6 doi:10.1371/journal.ppat.0010006.
5. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-8.
6. Harris RS, (2008) Enhancing immunity to HIV through APOBEC. Nat Biotechnol 26: 1089-90.
7. Malim MH, (2006) Natural resistance to HIV infection: The Vif-APOBEC interaction. C R Biol 329: 871-5.
8. Kypr J, Mrazek J, (1987) Unusual codon usage of HIV. Nature 327 (6117): 20.
9. Berkhout B, van Hemert FJ, (1994) The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res 22: 1705-11.
10. Berkhout B, de Ronde A, (2004) APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. Aids 18: 1861-3.
11. Gao F, Chen Y, Levy DN, Conway JA, Kepler TB, et al. (2004) Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J Virol 78: 2426-33.
12. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 105: 7552-7.
13. Deforche K, Camacho R, Laethem KV, Shapiro B, Moreau Y, et al. (2007) Estimating the Relative Contribution of dNTP Pool Imbalance and APOBEC3G/3F Editing to HIV Evolution In Vivo. J Comput Biol 14: 1105-14.
14. Soros VB, Yonemoto W, Greene WC, (2007) Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 3: e15 doi:10.1371/journal.ppat.0030015.
15. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
16. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH, (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231 doi:10.1371/journal.ppat.1000231.
17. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 11: 435-42.
18. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. (2004) APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res 32: 2421-9.
19. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S, (1994) G→A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc Natl Acad Sci U S A 91: 3092-6.
20. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, et al. (2008) Conserved footprints of APOBEC3G on Hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. J Virol 82: 8743-61.
21. Sheehy AM, Gaddis NC, Malim MH, (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9 (11): 1404-7.
22. Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN, (2007) The role of APOBEC3G/F-mediated hypermutation in the control of HIV-1 in Elite Suppressors. J Virol 82: 3125-30.
23. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, et al. (2005) G→A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J Virol 79: 1975-80.
24. Janini M, Rogers M, Birx DR, McCutchan FE, (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. J Virol 75: 7973-86.
25. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 15: 166-70.
26. Holmes RK, Koning FA, Bishop KN, Malim MH, (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282: 2587-95.
27. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH, (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 5: e1000330 doi:10.1371/journal.ppat.1000330.
28. Xu H, Chertova E, Chen J, Ott DE, Roser JD, et al. (2006) Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360: 247-56.
29. Kaiser SM, Emerman M, (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J Virol 80: 875-82.
30. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. (2007) Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J Virol 81: 7099-110.
31. Langlois MA, Neuberger MS, (2008) Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J Virol 82: 4660-4.
32. Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, et al. (2006) Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B. J Virol 80: 3679-83.
33. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S, (2006) Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res 34: 4677-84.
34. Jern P, Russell RA, Pathak VK, Coffin JM, (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog pp. e1000367 doi:10.1371/journal.ppat.1000367.
35. Furukawa A, Nagata T, Matsugami A, Habu Y, Sugiyama R, et al. (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. Embo J 28: 440-51.
36. Pybus OG, Rambaut A, Belshaw R, Freckleton RP, Drummond AJ, et al. (2007) Phylogenetic evidence for deleterious mutation load in RNA viruses and its contribution to viral evolution. Mol Biol Evol 24: 845-52.
37. Sanjuan R, Moya A, Elena SF, (2004) The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci U S A 101: 8396-401.
38. Wang Q, Barr I, Guo F, Lee C, (2008) Evidence of a novel RNA secondary structure in the coding region of HIV-1 pol gene. Rna 14: 2478-88.
39. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-9.
40. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS, (2003) DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nat Immunol 4: 641-3.
41. Yang B, Chen K, Zhang C, Huang S, Zhang H, (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J Biol Chem 282: 11667-75.
42. Sadler HA, Stenglein MD, Harris RS, Mansky LM, (2010) APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 84: 7396-404.
43. Kim EY, Bhattacharya T, Kunstman K, Swantek P, Koning FA, et al. (2010) Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 84: 10402-5.
44. Kapoor A, Jones M, Shafer RW, Rhee SY, Kazanjian P, et al. (2004) Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay. J Virol 78: 7112-23.
45. Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, et al. (2011) Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS ONE 6: e20357 doi:10.1371/journal.pone.0020357.
46. Svarovskaia ES, Moser MJ, Bae AS, Prudent JR, Miller MD, et al. (2006) MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol 44: 4237-41.
47. D'Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, et al. (2011) Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. AIDS Res Hum Retroviruses 27: 201-9.
48. Hazen R, Lanier ER, (2003) Relative anti-HIV-1 efficacy of lamivudine and emtricitabine in vitro is dependent on cell type. J Acquir Immune Defic Syndr 32: 255-8.
49. Turriziani O, Schuetz JD, Focher F, Scagnolari C, Sampath J, et al. (2002) Impaired 2′,3′-dideoxy-3′-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11. Biochem J 368: 325-32.
50. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, et al. (1999) MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5: 1048-51.
51. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, et al. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A 97: 7476-81.
52. Bantia S, Ananth SL, Parker CD, Horn LL, Upshaw R, (2003) Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor-BCX-1777. Int Immunopharmacol 3: 879-87.
53. Ebrahimi D, Anwar F, Davenport MP, (2011) APOBEC3 has not left an evolutionary footprint on the HIV-1 genome. J Virol 85: 9139-46.
54. Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5: e1000414 doi:10.1371/journal.ppat.1000414.
55. Fourati S, Malet I, Binka M, Boukobza S, Wirden M, et al. (2010) Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. Aids 24: 2313-21.
56. Mulder LC, Ooms M, Majdak S, Smedresman J, Linscheid C, et al. (2010) Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes. J Virol 84: 9613-7.
57. Bourara K, Liegler TJ, Grant RM, (2007) Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog 3: e153 doi:10.1371/journal.ppat.0030153.
58. Mulder LC, Harari A, Simon V, (2008) Cytidine deamination induced HIV-1 drug resistance. Proc Natl Acad Sci U S A 105: 5501-6.
59. Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, et al. (2008) HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c proteome: immune escape and viral load. J Virol 82: 6434-46.
60. Chen J, Hong K, Jia M, Liu H, Zhang Y, et al. (2007) Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC). Retrovirology 4: 62.
61. Yu XG, Lichterfeld M, Addo MM, Altfeld M, (2005) Regulatory and accessory HIV-1 proteins: potential targets for HIV-1 vaccines? Curr Med Chem 12 (6): 741-7.
62. Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M, (2002) Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection. DNA Cell Biol 21: 671-8.
63. Novitsky V, Cao H, Rybak N, Gilbert P, McLane MF, et al. (2002) Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 76: 10155-68.
64. Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, et al. (2001) Vpr is preferentially targeted by CTL during HIV-1 infection. J Immunol 167: 2743-52.
65. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
66. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80: 9259-69.
67. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, et al. (2008) Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82: 8172-82.
68. Vazquez-Perez JA, Ormsby CE, Hernandez-Juan R, Torres KJ, Reyes-Teran G, (2009) APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6: 23.
69. Ulenga NK, Sarr AD, Hamel D, Sankale JL, Mboup S, et al. (2008) The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Res Hum Retroviruses 24: 1285-90.
70. Piantadosi A, Humes D, Chohan B, McClelland RS, Overbaugh J, (2009) Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J Virol 83: 7805-14.
71. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH, (1995) Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol 69: 4166-72.
72. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004. 14: 1392-6.
73. Bishop KN, Holmes RK, Sheehy AM, Malim MH, (2004) APOBEC-mediated editing of viral RNA. 305: 645.
74. Reed SE, Staley EM, Mayginnes JP, Pintel DJ, Tullis GE, (2006) Transfection of mammalian cells using linear polyethylenimine is a simple and effective means of producing recombinant adeno-associated virus vectors. J Virol Methods 138: 85-98.
75. Tseng WC, Haselton FR, Giorgio TD, (1997) Transfection by cationic liposomes using simultaneous single cell measurements of plasmid delivery and transgene expression. J Biol Chem 272: 25641-7.
76. Staden R, Beal KF, Bonfield JK, (2000) The Staden package Methods Mol Biol 132: 115-30.
77. Rose PP, Korber BT, (2000) Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 16: 400-1.
78. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, (2008) Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 376: 101-11.